Altogether, these data suggest that the addition of the CDK2 inhibitor to CDK4/6 and CXCR1/2 inhibitors not only reduces melanoma tumor cell viability and tumor growth more effectively in BRAFWTNRASWT melanoma cells but also results in a less immunosuppressive tumor immune microenvironment. The gene discussed is CDK4; the disease is melanoma.